Rare Diseases: Innovation, Investment, and Unmet Needs – Strategic Intelligence

Explore the rare disease market, including drug development by therapy area and modality, leading companies, M&A activity, licensing deals and regulatory access challenges.

Why Does the Rare Disease Market Matter?

The rare disease market represents a significant but structurally underserved opportunity for pharmaceutical and biotechnology companies. Drug development activity is expanding across therapy areas, indications and modalities, while companies are increasingly using mergers and acquisitions (M&A) and licensing agreements to strengthen their portfolios and build capabilities.

However, development activity remains uneven. Oncology accounts for a substantial share of rare disease pipeline activity but is also the least mature area of the pipeline. At the same time, orphan drug designations continue to increase, highlighting growing regulatory recognition of rare disease treatments. Yet regulatory approval does not necessarily translate into patient access, with reimbursement and availability remaining important challenges.

GlobalData’s Rare Disease Theme Analysis examines the evolving rare disease landscape, identifying where development activity is concentrated, which companies are most active and how dealmaking and regulatory developments are shaping the market.

Key Insights in the Rare Disease Market

• Underserved market opportunity: Rare diseases represent a structurally underserved area of healthcare, creating opportunities and challenges for pharmaceutical and biotechnology developers.
• Oncology pipeline concentration: Rare disease drug development is heavily weighted towards oncology, although this remains the least mature part of the pipeline.
• Accelerating deal activity: M&A activity in rare disease has increased sharply, with 2026 already representing the biggest year on record for M&A deals.
• Growing orphan drug designations: Orphan drug designations continue to rise, reflecting sustained development activity and regulatory attention across rare disease indications.
• Regulatory approval and patient access: Approval does not guarantee that patients can access treatments, making market access and the evolving regulatory environment important considerations.
• Company portfolio expansion: Leading companies are using acquisitions and licensing agreements to build and strengthen their rare disease positions.
• Changing development landscape: Drug development activity varies across therapy areas, indications and modalities, creating a diverse and evolving competitive environment.

Scope

What Will You Learn from This Rare Disease Theme Analysis?

• Market landscape: What are the key characteristics and opportunities within the structurally underserved rare disease market?
• Pipeline concentration: Which therapy areas and indications account for the greatest share of rare disease drug development?
• Modality trends: Which drug modalities are being pursued across the rare disease development landscape?
• Pipeline maturity: How does development maturity vary across therapy areas, particularly in oncology?
• Leading companies: Which companies are most active in rare disease development, and how are they building their positions?
• M&A activity: How has rare disease dealmaking evolved, and what does the record M&A activity in 2026 indicate?
• Licensing strategies: How are companies using licensing agreements to expand their rare disease portfolios?
• Orphan drug designations: How are orphan drug designations developing across the market?
• Regulatory and access environment: Why can regulatory approval fail to translate into treatment availability for patients?

Who Should Buy This Rare Disease Theme Analysis?

This report is designed for organisations evaluating rare disease development, investment and commercial opportunities, including:

• Pharmaceutical companies: Understand pipeline concentration, emerging opportunities and competitive activity across rare disease therapy areas.
• Biotechnology companies: Assess development trends, drug modalities and potential licensing or partnership opportunities.
• Business development and licensing teams: Monitor M&A activity, licensing agreements and the strategies of active market participants.
• Investors and financial analysts: Evaluate dealmaking trends, pipeline maturity and the commercial potential of rare disease assets.
• Research and development leaders: Understand where drug development is concentrated across therapy areas, indications and modalities.
• Market access and regulatory teams: Assess the evolving orphan drug designation landscape and challenges affecting patient access after approval.
  

  

How Companies Use This Rare Disease Analysis

Organisations can use this analysis to:

• Identify development opportunities: Assess where drug development is concentrated across therapy areas, indications and modalities.
• Benchmark pipeline activity: Understand the maturity of development programmes and identify areas where the pipeline remains less advanced.
• Inform M&A strategies: Monitor dealmaking trends and identify how acquisitions are being used to build rare disease portfolios.
• Evaluate licensing opportunities: Understand company activity and the role of licensing agreements in expanding rare disease development capabilities.
• Assess competitive positioning: Identify the most active companies and evaluate how they are building their presence in the market.
• Monitor regulatory developments: Track orphan drug designation trends and understand the changing regulatory environment.
• Evaluate patient access challenges: Consider the gap between regulatory approval and actual treatment availability when assessing commercial opportunities.

Reasons to Buy

Benchmark the Rare Disease Landscape

Gain a structured view of the rare disease market through analysis of:

• Drug development activity across therapy areas.
• Pipeline concentration by indication and modality.
• Development maturity across key therapy areas.
• Oncology’s position within the rare disease pipeline.
• Leading companies active in rare disease development.
• Mergers and acquisitions across the sector.
• Licensing agreements and portfolio-building strategies.
• Orphan drug designation trends.
• Regulatory developments and patient access challenges.

Built on GlobalData Intelligence

GlobalData combines pharmaceutical research, pipeline analysis and industry intelligence to provide insight into the rare disease landscape. This report brings together drug development trends, company activity, dealmaking and regulatory analysis to help decision-makers understand the market’s evolving opportunities and challenges.

Act Now to Identify Opportunities in the Rare Disease Market

As drug development expands and dealmaking accelerates, understanding pipeline maturity, company strategies and patient access challenges is essential. Use GlobalData’s Rare Disease Theme Analysis to assess development activity, monitor M&A and licensing trends, and identify opportunities across the evolving rare disease landscape.